Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formulation A is an experimental topical cream containing 1.0% salicylic acid, developed by researchers at Northwestern University for the treatment of mild to moderate acne vulgaris. Salicylic acid is a beta-hydroxy acid that exerts its therapeutic effect through keratolytic activity, softening and dissolving the intercellular cement that holds epithelial cells together in the stratum corneum. This process facilitates the shedding of dead skin cells and the clearance of comedones, which are central to the pathogenesis of acne. Formulation A was evaluated in a Phase 2 split-face, paired-comparison pilot trial (NCT00881153) to assess its safety and efficacy relative to another 1.0% salicylic acid cream (Formulation B) in a pediatric and young adult population aged 13 to 35.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Formulation A.